Advertisement

Role of Resistin in Heart Failure in the Elderly

  • Yasuchika TakeishiEmail author
Chapter

Abstract

Resistin is derived mainly from fat tissue in rodents, and serum levels are elevated in animal models of obesity and insulin resistance. Recent clinical studies have demonstrated that circulating resistin is associated with inflammation, coronary atherosclerosis, renal dysfunction, adverse prognosis in patients with atherothrombotic ischemic stroke, and heart failure. In the population-based observational study, increased circulating levels of resistin are associated with incidence of new-onset heart failure, even after accounting for prevalent coronary heart disease, obesity, insulin resistance, and inflammation. In the elderly, incident heart failure rates (per 1,000 person-years) elevate with increasing baseline resistin concentrations. In addition, resistin is strongly associated with risk for incident heart failure in Cox proportional hazard models controlling for clinical variables, inflammatory biomarkers, and measures of adiposity.

Keywords

Heart Failure Acute Decompensated Heart Failure Resistin Level Prevalent Coronary Heart Disease Incident Heart Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Yi-Hao Y, Ginsberg HN. Adipocyte signaling and lipid homeostasis. Circ Res. 2005;96:1042–52.CrossRefGoogle Scholar
  2. 2.
    Petersen S. GI: Etiology of insulin resistance. Am J Med. 2006;119(5 Suppl 1):S10–6.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine. 2006;29:81–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf). 2006;64:355–65.Google Scholar
  5. 5.
    Beltowski J. Adiponectin and resistin–new hormones of white adipose tissue. Med Sci Monit. 2003;9:RA55–61.PubMedGoogle Scholar
  6. 6.
    Kunnari A, Ukkola O, Kesaeniemi YA. Resistin polymorphisms are associated with cerebrovascular disease in Finnish type 2 diabetic patients. Diabet Med. 2005;22:583–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Diez JJ, Iglesias P, Fernandez-Reyes MJ, Aguilera A, Bajo MA, Alvarez-Fidalgo P, et al. Serum concentration of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf). 2005;62:242–9.CrossRefGoogle Scholar
  8. 8.
    Burnett MS, Devaney JM, Adenika RJ, Lindsay R, Howard BV. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. J Clin Endocrinol Metab. 2006;91:64–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–12.PubMedCrossRefGoogle Scholar
  10. 10.
    Jung HS, Park KH, Cho YM, Chung SS, Cho HJ, Kim SJ, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res. 2006;69:76–85.PubMedCrossRefGoogle Scholar
  11. 11.
    Rajala MW, Obici S, Scherer PE. Rossetti: Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest. 2003;111:225–30.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Benerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, et al. Regulation of fasted blood glucose by resistin. Science. 2004;303:1195–8.CrossRefGoogle Scholar
  13. 13.
    Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111:932–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Ellington AA, Malik AR, Klee GG, Turner ST, Rule AD, Mosley TH, et al. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension. 2007;50:708–14.PubMedCrossRefGoogle Scholar
  15. 15.
    Efstathiou SP, Tsiakou AG, Tsioulos DI, Panagiotou TN, Pefanis AV, Achimastos AD, et al. Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin Chim Acta. 2007;378:78–85.PubMedCrossRefGoogle Scholar
  16. 16.
    Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2008;155:75–81.PubMedCrossRefGoogle Scholar
  17. 17.
    Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068–72.PubMedCrossRefGoogle Scholar
  18. 18.
    Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–50.PubMedCrossRefGoogle Scholar
  19. 19.
    Niizeki T, Takeishi Y, Arimoto T, Okuyama H, Takabatake N, Fukui A, Tachibana H, Nozaki N, Hirono O, Tsunoda Y, Miyashita T, Takahashi H, Koyama Y, Shishido T, Kubota I. Serum heart-type fatty acid binding protein predicts cardiac events in the elderly chronic heart failure patients. J Cardiol. 2005;46:9–15.PubMedGoogle Scholar
  20. 20.
    Takeishi Y, Niizeki T, Arimoto T, Nozaki N, Hirono O, Nitobe J, et al. Serum resistin is associated with high risk in patients with congestive heart failure: A novel link between metabolic signals and heart failure. Circ J. 2007;71:460–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Schulze PC, Biolo A, Gopal D, Shahzad K, Balog J, Fish M, et al. Dynamics in insulin resistance and plasma levels of adipokines in patients with acute decompensated and chronic heart failure. J Card Fail. 2011;17:1004–11.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Frankel DS, Ramachandran VS, D’Agostino RB, Benjamin EJ, Levy D, Wang TJ, et al. Resistin, adiponectin, and risk of heart failure. The Framingham Offspring Study. J Am Coll Cardiol. 2009;53:754–62.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Buttler J, Kalogeropoulos A, Georgiopoulou V, Rhonda B, Rodondi N, Garcia M, et al. Incident heart failure prediction in the elderly: The Health ABC heart failure score. Circ Heart Fail. 2008;1:125–33.CrossRefGoogle Scholar
  24. 24.
    Butler J, Kalogeropoulos A, Georgiopoulou V, Rekeneire N, Rodondi N, Smith AL, et al. Serum resistin concentrations and risk of new onset heart failure in older persons. Arterioscler Thromb Vasc Biol. 2009;29:1144–9.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Zhang MH, Na B, Schiller NB, Whooley MA. Association of resistin with heart failure and mortality in patients with stable coronary heart disease: data from the heart and soul study. J Card Fail. 2011;17:24–30.PubMedCrossRefGoogle Scholar
  26. 26.
    Rienstra M, Sun JX, Lubitz SA, Frankel DS, Vasan RS, Levy D, et al. Plasma resistin, adiponectin, and risk of incidental atrial fibrillation: The Framingham Offspring study. Am Heart J. 2012;163:119–24.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Cardiology and HematologyFukushima Medical UniversityFukushimaJapan

Personalised recommendations